2007 Credit Suisse Healthcare Conference to Webcast Millennium Presentation
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
The presentation will include an overview of the Company, an update onclinical trials for VELCADE(R) (bortezomib) for Injection and other productcandidates, and a review of upcoming milestones. The presentation will bedelivered at 1:00 p.m. ET on Tuesday, November 13, 2007 from the ArizonaBiltmore Resort in Phoenix, Arizona. The presentation will be archived for 30days.
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical companybased in Cambridge, Mass., markets VELCADE, a novel cancer product, and has arobust clinical development pipeline of product candidates. The Company'sresearch, development and commercialization activities are focused in twotherapeutic areas: oncology and inflammation. By applying its knowledge ofthe human genome, understanding of disease mechanisms and industrialized drugdiscovery platform, Millennium is developing an exciting pipeline ofinnovative product candidates. The Company's website ishttp://www.millennium.com.
Editors' Note: This press release is also available under the Mediasection of the Company's website at: http://www.millennium.com.
SOURCE Millennium Pharmaceuticals, Inc.
You May Also Like